

Supplemental Table S1. Baseline Characteristics of Study Participants According to Treatment Group (per Protocol Set)

Characteristic	Cilostazol	Aspirin	<i>P</i> value
Number	37	53	
Age, yr	61±7	60±6	0.501
Male sex	29 (78.4)	30 (56.6)	0.043
Height, cm	166±8	163±7	0.088
Weight, kg	68±9	66±12	0.322
Smoking	11 (29.7)	7 (13.2)	0.065
Non-drinkers	19 (51.4)	17 (32.1)	0.082
Waist circumference, cm	90±8	88±10	0.328
Systolic blood pressure, mm Hg	129±13	128±16	0.713
Diastolic blood pressure, mm Hg	79±13	75±11	0.201
Heart rate, bpm	74±12	78±11	0.131
Previous cilostazol exposure	7 (18.9)	6 (11.3)	0.369
History of cardiovascular disease	4 (10.8)	3 (5.7)	0.440
Hypertension	22 (59.5)	28 (52.8)	0.667
Dyslipidemia	32 (86.5)	46 (86.8)	1.000
Albuminuria	0	0	
White blood cells, ×10 ³ /mm ³	6.16±1.68	6.54±1.57	0.288
Hemoglobin, g/dL	14.4±1.6	13.9±1.4	0.141
Platelet count, ×10 ³ /μL	229±65	233±55	0.748
Fasting glucose, mg/dL	135±34	142±33	0.387
HbA1c, %	7.2±1.6	7.3±1.3	0.629
Fasting insulin, μIU/mL	8.2±3.8	9.6±9.6	0.351
HOMA-IR	2.78±1.43	3.32±3.02	0.261
HOMA-β, %	48.3±26.5	53.8±69.4	0.601
Total cholesterol, mg/dL	134±46	139±32	0.480
Triglycerides, mg/dL	116±68	147±75	0.044
HDL-cholesterol, mg/dL	54±12	52±20	0.607
LDL-cholesterol, mg/dL	76±27	77±29	0.834
Blood urea nitrogen, mg/dL	15±4	16±6	0.170
Serum creatinine, mg/dL	1.80±5.94	1.52±5.11	0.812
eGFR, mL/min/1.73 m ²	91.1±11.9	89.8±16.5	0.657
AST, IU/L	23±7	25±12	0.331
ALT, IU/L	23±12	24±14	0.794
VerifyNow, ARU	637±34	639±32	0.759
PFA-100, sec	136±46	138±32	0.832
CRP, ng/mL	1,706±5,355	902±1,417	0.299
CD40 ligand, pg/mL	1,992±1,432	1,747±1,621	0.451
Diabetes medication			
Metformin	21 (56.8)	41 (77.4)	0.063
Sulfonylurea	9 (24.3)	21 (39.6)	0.174
Thiazolidinedione	3 (8.1)	5 (9.4)	1.000
DPP-4 inhibitor	22 (59.5)	35 (66)	0.657
SGLT2 inhibitor	8 (21.6)	9 (17)	0.596

(Continued to the next page)

Supplemental Table S1. Continued

Characteristic	Cilostazol	Aspirin	<i>P</i> value
Hypertension medication	20 (54.1)	24 (45.3)	0.521
Angiotensin II receptor blocker	17 (45.9)	14 (26.4)	0.072
ACE inhibitor	0	2 (3.8)	0.510
Diuretics	0	1 (1.9)	1.000
Calcium channel blockers	4 (10.8)	7 (13.2)	1.000
β -Blocker	2 (5.4)	2 (3.8)	1.000
Other hypertension medication	3 (8.1)	4 (7.5)	1.000
Dyslipidemia medication	33 (89.2)	50 (94.3)	0.444
Statin	32 (86.5)	50 (94.3)	0.266
Fibrate	1 (2.7)	2 (3.8)	1.000
Other dyslipidemia medication	2 (5.4)	5 (9.4)	0.695

Values are expressed as mean \pm standard deviation or number (%).

HbA1c, hemoglobin A1c; HOMA-IR, homeostatic model assessment for insulin resistance; HOMA- β , homeostatic model assessment for β cell function; HDL, high density lipoprotein; LDL, low density lipoprotein; eGFR, estimated glomerular filtration rate; AST, aspartate transferase; ALT, alanine transaminase; ARU, aspirin response units; CRP, C-reactive protein; CD40, cluster of differentiation 40; DPP-4, dipeptidyl peptidase 4; SGLT-2, sodium-glucose cotransporter-2; ACE, angiotensin-converting-enzyme.